MGN 3

Drug Profile

MGN 3

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiwa Pharmaceutical
  • Developer Daiwa Pharmaceutical; Lane Labs
  • Class Antineoplastics; Antivirals
  • Mechanism of Action B cell stimulants; Immunostimulants; Interleukin 10 stimulants; Interleukin 6 stimulants; Interleukin 8 modulators; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lyme disease
  • No development reported Cancer; HIV infections

Most Recent Events

  • 08 Apr 2003 No development reported - Phase-II for Cancer in USA (unspecified route)
  • 08 Apr 2003 No development reported - Preclinical for HIV infections treatment in USA (unspecified route)
  • 03 Apr 2001 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top